-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AstraZeneca and Daiichi Sankyo today announced that the U.
Managing FDA Lung Cancer NSCLC
The filing is based on data from the pivotal Phase II DESTINY-Lung01 trial, in which the HER2-targeting ADC demonstrated a 54.
"Enhertu has the potential to become a new standard of care for this patient population," said Susan Galbraith, head of oncology research and development at AstraZeneca
If approved, this would be Enhertu's third oncology indication
If approved, this would be Enhertu's third oncology indication
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5551523 https://firstwordpharma.
com/story/5551523
Leave a comment here